|
Vectura Group plc - SWOT AnalysisPublished by: Datamonitor Published: May. 20, 2008 - 22 Pages Table of Contents
AbstractDatamonitor's Vectura Group plc - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.Vectura Group (Vectura) is a pulmonary drug development group focused principally on the development of a range of inhaled pharmaceuticals for the treatment of respiratory and neurological diseases. The group has eight marketed products and a portfolio of drugs in clinical and pre-clinical development. In addition, Vectura offers its formulation and inhalation capabilities to other pharmaceutical companies on a licensing basis. The group is headquartered in Wiltshire, United Kingdom and employed 236 people as of March 31, 2007. The group recorded revenues of £14.1 million during the fiscal year ended March 2007, an increase of 67.1% over 2006. The operating loss of the group was £11.3 million during fiscal year 2007, when compared to an operating loss of £8.5 million during fiscal 2006. The net loss was £6.8 million in fiscal year 2007, when compared to a net loss of £6.5 million during fiscal 2006. Scope of the Report
Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||